Drug Database
AN

anandamide (anandamide)

✓ Approved

Yissum · CNR1

什么是 anandamide?

anandamide 是一种治疗药物,由Yissum研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

商品名anandamide
公司Yissum
分子靶点CNR1, CNR2
给药途径Unknown
状态Approved

作用机制

分子靶点

anandamide 作用于 2 个分子靶点:

CNR1cannabinoid receptor 1 (CNR, CB1A)
CNR2cannabinoid receptor 2 (CX5, CB-2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

anandamide 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Psychiatric disordersAnorexia nervosa✓ Approved
Psychiatric disordersBulimia nervosa✓ Approved

相关研究文献

PubMedNeurobiology of disease2026-11-18

Modulation of the endocannabinoid system through diet, physical activity and microbiome in the new era of multiple sclerosis.

Maccarrone Giuseppe G, Montaguti Luca L, Bruno Antonio A, Borrelli Angela A et al.

Multiple sclerosis (MS) is a chronic immune-mediated disorder characterized by neuroinflammation, inflammatory synaptopathy, and progressive neurodegeneration. Increasing evidence identifies the endocannabinoid system (ECS) as a regulator of synaptic transmission, neuroinflammatory tone, and neuroplasticity; however, its translational relevance in people with MS remains incompletely established. Cannabinoid-based compounds have their most established clinical role in symptomatic treatment, particularly for residual symptoms within the spasticity-plus syndrome, whereas effects on excitotoxicity, microglial activation, and neuroinflammation are supported mainly by mechanistic and preclinical evidence. Lifestyle-related factors, including physical activity, diet, and gut microbiome composition, have been associated with ECS-related signaling changes in healthy individuals and experimental models, but direct evidence of ECS-mediated effects in MS remains limited. Physical activity can increase circulating levels of the endocannabinoid anandamide in healthy individuals, while dietary components may influence ECS-related pathways through polyunsaturated fatty acids and phytochemicals; however, direct ECS-mediated clinical effects of either intervention in MS have not been demonstrated. Experimental evidence also supports bidirectional interactions between the gut microbiome and the ECS, although their clinical relevance in MS remains uncertain. Overall, these findings support a biologically plausible, hypothesis-generating framework linking lifestyle factors and ECS-related pathways alongside disease modifying treatments, without demonstrating causal mediation or disease-modifying efficacy. This review integrates preclinical and clinical evidence to distinguish established symptomatic effects from biological plausibility and indirect associations, and highlights priorities for prospective validation and personalized multimodal MS management.

PMID 43051379
阅读全文 →
PubMedJournal of lipid research2026-11-17

N-arachidonoyl-phosphatidylethanolamine metabolizing through lyso-NAPE selectively inhibits mesenchymal tumor invasion.

Juhász Kata K, Schmidt János J, Pammer Milán M, Sándor Nikolett N et al.

Most anticancer drugs target proliferation or viability, but vast majority of patients' deaths result from metastasis initiated by the invading primary tumor. Development of effective anti-invasive medicines therefore remains an important challenge. Lipases of N-arachidonoyl-phosphatidylethanolamine (NAPE) have been implicated as putative tumor suppressors. To identify anti-invasive lipids, we investigated the effect of NAPE on tumor invasion while tracking its metabolism in 3D Matrigel-embedded spheroids. Unlike in healthy tissues analyzed before, NAPE was metabolized mainly indirectly through lyso-NAPE and glycerophospho-anandamide (GP-AEA) to AEA in any tumors tested. NAPE and its major metabolite, lyso-NAPE showed a selective effect against mesenchymal invasion while suppressing Rac1 activity. Spheroids with amoeboid invasion could be made vulnerable to both NAPE and lyso-NAPE by ROCK inhibition that switched to Rac1-driven mesenchymal invasion. Anti-invasive effect of lyso-NAPE was found distinguishable from the further downstream GP-AEA, and independent of AEA and lysophosphatidic acid (LPA) effects. A biochemical blockade of lyso-NAPE but not AEA synthesis, by administering the structurally analogous non-mammalian diether-NAPE, resulted in a dramatic loss of the anti-invasive effect. Importantly, directly exposing tumor spheroids to lyso-etherNAPE retained the anti-invasive effect, while treatment with the naturally more abundant lyso-plasmalogenNAPE was ineffective against tumor invasion, despite inversely changing AEA levels during their metabolism. Altogether, mapping the cancer lipid metabolism in a tissue-like invasion model unraveled NAPE and its major metabolite lyso-NAPE with a potent anti-invasive effect. N-acyl-PEs being preclinically proven lipid components of liposome-based drug delivery systems, NAPE and its metabolite lyso-NAPE are proposed as potential anti-metastatic agents.

PMID 43044928
阅读全文 →
PubMedRheumatology (Oxford, England)2026-11-16

Significant changes in circulating endocannabinoids correlate with disease severity in rheumatoid arthritis: a cross-sectional study.

Govrin Eri E, Halpert Gilad G, Nissan Johnatan J, Ben-Shabat Niv N et al.

To investigate alterations in plasma concentrations of circulating endocannabinoids and endocannabinoid-like molecules in patients with rheumatoid arthritis (RA) and to assess their associations with the Disease Activity Score 28 with Erythrocyte Sedimentation Rate (DAS28-ESR). The study was designed as a single-center, cross-sectional investigation. Female patients with RA (n = 43; aged ≥18 years) were recruited at Sheba Medical Center, Israel, and diagnosed according to the 2010 ACR/EULAR classification criteria. Healthy females (n = 38) served as controls. Plasma levels of 25 endocannabinoids and endocannabinoid-like molecules were quantified using solid-phase extraction followed by electrospray ionization liquid chromatography-high-resolution tandem mass spectrometry (ESI-LC-HRMS/MS). Statistical analyses included group comparisons and FDR-corrected linear regression models assessing associations between DAS-28-ESR and metabolite levels, adjusted for age and cannabis use. Several endocannabinoids, including 2-arachidonyl glycerol ether (2-AGE), 2-linoleoyl glycerol (2-LG), 2-oleoyl glycerol (2-OG), 2-palmitoyl glycerol (2-PG), 2-SG, linoleoyl-phenylalanine, linolenic acid (LnA), N-O-leucine, and palmitoylethanolamide (PEA), were significantly elevated in RA patients compared with controls (p = 0.015, p < 0.001, p < 0.001, p < 0.001, p = 0.027, p < 0.001, p = 0.034, p < 0.001, and p = 0.002, respectively). In contrast, anandamide (AEA), N-oleoyl alanine, and O-AEA were significantly reduced (p = 0.012, p < 0.001, and p < 0.001, respectively). Notably, plasma levels of AEA, PEA, and oleoylethanolamide (OEA) correlated significantly with DAS28-ESR scores (p = 0.015, p = 0.008, and p = 0.012, respectively). Specific endocannabinoids and endocannabinoid-like molecules are dysregulated in RA and correlate with disease activity, suggesting potential roles as biomarkers and therapeutic targets.

PMID 43035947
阅读全文 →
PubMedJournal of cannabis research2026-11-11

A human microbiota-associated translational mouse model reveals sex-specific responses to cannabidiol and cannabigerol.

Keohane Eva E, Poehlein Lance L, Chaparro Jacqueline M JM, Wrigley Scott D SD et al.

Cannabidiol (CBD) and cannabigerol (CBG) are non-psychoactive phytocannabinoids with therapeutic potential, yet their effects on host physiology and interactions with the gut microbiome remain poorly defined. Here, we used a translational mouse model colonized with human-associated microbiotas to investigate the effects of oral CBD and CBG intervention on microbial composition, endocannabinoid signaling, and intestinal protein expression. While neither phytocannabinoids altered overall gut microbiome diversity, both induced sex-specific shifts in bacterial taxa associated with mucin utilization and short-chain fatty acid production. Circulating concentrations of CBD were higher than those of CBG, and females exhibited higher plasma phytocannabinoid concentrations than males. Males treated with CBD had elevated anandamide (AEA) levels, potentially reflecting inhibition of fatty acid amide hydrolase, consistent with upregulation of serine protease inhibitors observed in ileal proteomes. Females also accumulated more subcutaneous adipose tissue with both CBD and CBG treatment resulting in greater total CBD storage in this depot. Collectively, these findings suggest sex-specific interactions between phytocannabinoids, the endocannabinoid system, and the gut microbiome, underscoring the importance of considering biological sex in cannabinoid research and informing personalized therapeutic strategies.

PMID 43010098
阅读全文 →
PubMedThe international journal of neuropsychopharmacology2026-11-10

The Relationship Between Manic Episodes and Serum Endocannabinoid Levels in Bipolar Disorder.

Özel Sarpkan S, Görgülü Yasemin Y, Topuz Ruhan Deniz RD

Endocannabinoids are involved in biological processes relevant to mood regulation, and altered circulating levels have been reported in bipolar disorder (BD). However, serum endocannabinoid levels have not previously been examined across mania and remission within the same patients and compared with healthy controls. This study evaluated serum palmitoylethanolamide (PEA), oleoylethanolamide (OEA), 2-arachidonoylglycerol (2-AG), anandamide (AEA), and C-reactive protein (CRP) levels in patients with BD during manic episodes and remission and in healthy controls. Fifty-one patients diagnosed with BD, manic episode, according to DSM-5-TR criteria, and 49 healthy controls were included. After discharge, 32 patients who attended outpatient follow-up visits were re-evaluated during remission. Serum PEA, OEA, 2-AG, AEA, and CRP levels were measured in all participants. Patients with BD were additionally assessed using the Young Mania Rating Scale, Hamilton Depression Rating Scale, and Positive and Negative Syndrome Scale. Serum PEA and OEA levels were significantly lower during manic episodes than in healthy controls. During remission, serum PEA and OEA levels did not differ significantly from those of healthy controls. In within-patient comparisons between manic episodes and remission, only serum PEA levels were significantly lower during manic episodes. This is the first study to assess serum endocannabinoid levels in patients with BD during both manic episodes and remission, together with healthy controls. PEA and OEA levels were significantly lower during mania and returned to values comparable to healthy controls during remission. These findings suggest that endocannabinoid-related mechanisms may have potential as future biomarkers and therapeutic targets in mood regulation.

PMID 43007332
阅读全文 →
PubMedFrontiers in pharmacology2026-11-05

Live combined bifidobacterium attenuates rivaroxaban-associated colonic bleeding in mice: evidence for a substantial gut microbiota-dependent component.

Chen Xiaowen X, Lin Yuze Y, Huang Youqi Y, Zeng Linghong L et al.

Rivaroxaban, a direct oral anticoagulant (DOAC), is widely prescribed for the prevention and treatment of thromboembolic disorders. However, its use is associated with an increased risk of gastrointestinal bleeding, the mechanisms of which remain incompletely understood. Effective strategies to relief such bleeding are also lacking. Because the gut microbiota plays a critical role in maintaining intestinal homeostasis, we investigated whether probiotics could mitigate anticoagulant-related bleeding and explored the underlying mechanisms. Using a rivaroxaban-induced mouse model of colonic bleeding, we found that treatment with live combined Bifidobacterium reduced occult blood in the feces, alleviated damage to colon tissue, and lowered serum levels of the inflammatory cytokines tumor necrosis factor-α and chemokine ligand 5. Integrated 16S rRNA sequencing and untargeted metabolomic analyses showed that LCB treatment was accompanied by alterations in the gut microbial community and fecal metabolic profile. Following antibiotic-mediated microbiota depletion, the overall ameliorative effect of LCB was attenuated, although partial responses, including a reduction in CXCL5, were retained. These findings support a substantial microbiota-dependent component of the full ameliorative phenotype. Untargeted metabolomic analysis identified a metabolite feature putatively annotated as anandamide that showed a nominal decrease following rivaroxaban administration and a nominal increase after LCB treatment. However, these differences did not remain significant after false discovery rate (FDR) correction and were therefore considered exploratory. The same feature also showed a nominal increase following LCB treatment in antibiotic-treated mice without corresponding restoration of the overall ameliorative phenotype, suggesting that this metabolic change alone was insufficient to account for the observed effects. To our knowledge, the present study provides initial evidence that LCB administered after the onset of fecal occult bleeding ameliorates rivaroxaban-associated colonic injury in mice. Collectively, these findings suggest that the overall ameliorative effect of LCB has a substantial gut microbiota-dependent component, whereas the putative anandamide signal represents a hypothesis-generating metabolic association that requires targeted quantitative and functional validation.

PMID 42984618
阅读全文 →

注册免费账户还可查看另外 4837 篇文献

免费注册查看全部文献 →

了解更多anandamide